Switch theme
Sign up to access all valuation multiples
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.
1963
14.8K+
LTM Revenue $4.4B
LTM EBITDA $1.0B
$14.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomerieux has a last 12-month revenue of $4.4B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Biomerieux achieved revenue of $4.3B and an EBITDA of $964M.
Biomerieux expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomerieux valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.9B | $4.3B | XXX | XXX | XXX |
| Gross Profit | $2.2B | $2.2B | XXX | XXX | XXX |
| Gross Margin | 55% | 52% | XXX | XXX | XXX |
| EBITDA | $753M | $964M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 23% | XXX | XXX | XXX |
| Net Profit | $486M | $384M | XXX | XXX | XXX |
| Net Margin | 12% | 9% | XXX | XXX | XXX |
| Net Debt | n/a | $19.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Biomerieux's stock price is EUR 115 (or $123).
Biomerieux has current market cap of EUR 13.6B (or $14.6B), and EV of EUR 13.6B (or $14.6B).
See Biomerieux trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.6B | $14.6B | XXX | XXX | XXX | XXX | $4.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Biomerieux has market cap of $14.6B and EV of $14.6B.
Biomerieux's trades at 3.3x LTM EV/Revenue multiple, and 14.1x LTM EBITDA.
Analysts estimate Biomerieux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biomerieux and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $14.6B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 15.1x | XXX | XXX | XXX |
| P/E | 31.4x | XXX | XXX | XXX |
| P/E/Growth | 1.8x | XXX | XXX | XXX |
| EV/FCF | 42.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiomerieux's NTM/LTM revenue growth is 7%
Biomerieux's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Biomerieux's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biomerieux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biomerieux and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 40% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomerieux acquired XXX companies to date.
Last acquisition by Biomerieux was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomerieux acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biomerieux founded? | Biomerieux was founded in 1963. |
| Where is Biomerieux headquartered? | Biomerieux is headquartered in France. |
| How many employees does Biomerieux have? | As of today, Biomerieux has 14.8K+ employees. |
| Who is the CEO of Biomerieux? | Biomerieux's CEO is Mr. Alexandre Merieux. |
| Is Biomerieux publicy listed? | Yes, Biomerieux is a public company listed on PAR. |
| What is the stock symbol of Biomerieux? | Biomerieux trades under BIM ticker. |
| When did Biomerieux go public? | Biomerieux went public in 2004. |
| Who are competitors of Biomerieux? | Similar companies to Biomerieux include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Biomerieux? | Biomerieux's current market cap is $14.6B |
| What is the current revenue of Biomerieux? | Biomerieux's last 12-month revenue is $4.4B. |
| What is the current EBITDA of Biomerieux? | Biomerieux's last 12-month EBITDA is $1.0B. |
| What is the current EV/Revenue multiple of Biomerieux? | Current revenue multiple of Biomerieux is 3.3x. |
| What is the current EV/EBITDA multiple of Biomerieux? | Current EBITDA multiple of Biomerieux is 14.1x. |
| What is the current revenue growth of Biomerieux? | Biomerieux revenue growth between 2023 and 2024 was 8%. |
| Is Biomerieux profitable? | Yes, Biomerieux is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
